title: Functional expression of novel peptide transporter in renal basolateral membranes.
abstract: We examined the peptide transport activity in renal basolateral membranes. [(14)C]glycylsarcosine (Gly-Sar) uptake in rat renal cortical slices was saturable and inhibited by excess dipeptide and aminocephalosporin cefadroxil. When several renal cell lines were screened for the basolateral peptide transport activity, Madin-Darby canine kidney (MDCK) cells were demonstrated to have the greatest transport activity. [(14)C]Gly-Sar uptake across the basolateral membranes of MDCK cells was inhibited by di- and tripeptide and decreased with decreases in extracellular pH from 7.4 to 5.0. The Michaelis-Menten constant value of [(14)C]Gly-Sar uptake across the basolateral membranes of MDCK cells was 71 microM. The basolateral peptide transporter in MDCK cells showed several different [(14)C]Gly-Sar transport characteristics in growth dependence, pH profile, substrate affinity, and sensitivities to chemical modifiers from those of the apical H(+)-peptide cotransporter of MDCK cells. The findings of the present investigation indicated that the peptide transporter was expressed in the renal basolateral membranes. In addition, from the functional characteristics, the renal basolateral peptide transporter was suggested to be distinguishable from known peptide transporters, i.e., H(+)-peptide cotransporters (PEPT1 and PEPT2) and the intestinal basolateral peptide transporter.
authors.affiliation: Department of Pharmacy, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto 606 - 8507, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Terada
authors.forename: K
authors.initials: K
authors.lastname: Sawada
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: H
authors.initials: H
authors.lastname: Saito
authors.forename: Y
authors.initials: Y
authors.lastname: Hashimoto
authors.forename: K
authors.initials: K
authors.lastname: Inui
mesh_terms: D002731:4-Chloromercuribenzenesulfonate / Q000494:pharmacology; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002250:Carbon Radioisotopes; D002352:Carrier Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis* / Q000737:chemistry; D002462:Cell Membrane / Q000378:metabolism*; D002478:Cells, Cultured; D004047:Diethyl Pyrocarbonate / Q000494:pharmacology; D004151:Dipeptides / Q000493:pharmacokinetics; D004285:Dogs; D006033:Glycylglycine / Q000494:pharmacology; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D007672:Kidney Cortex / Q000166:cytology / Q000378:metabolism*; D018374:LLC-PK1 Cells; D026901:Membrane Transport Proteins; D009842:Oligopeptides / Q000494:pharmacology; D009893:Opossums; D010455:Peptides / Q000378:metabolism*; D051381:Rats; D013379:Substrate Specificity; D013552:Swine
chemical_list: D002250:Carbon Radioisotopes; D002352:Carrier Proteins; D004151:Dipeptides; D026901:Membrane Transport Proteins; D009842:Oligopeptides; D010455:Peptides; C416263:renal basolateral peptide transporter; D006033:Glycylglycine; C004194:glycylsarcosine; D002731:4-Chloromercuribenzenesulfonate; C035647:glycyl-glycyl-glycine; D004047:Diethyl Pyrocarbonate